Completed PHASE2 INTERVENTIONAL 1-arm NCT01539824

A Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Colorectal Cancer

A Phase II, Single Arm, Investigative Study of IMM-101 in Combination With Radiation Induced Tumour Necrosis in Patients With Previously Treated Colorectal Cancer

Sponsor: Immodulon Therapeutics Ltd

Conditions Metastatic Colorectal Cancer

Interventions Mycobacterium obuense SBRT

Updated 7 times since 2017 Last updated: Oct 9, 2024 Started: May 30, 2012 Primary completion: Mar 27, 2014 Completion: Mar 27, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01539824, this PHASE2 trial focuses on Metastatic Colorectal Cancer and remains completed. Sponsored by Immodulon Therapeutics Ltd, it has been updated 7 times since 2012, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

7 versions recorded

Dec 2024 — Present [monthly]

Completed PHASE2
Sep 2024 — Dec 2024 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immodulon Therapeutics Ltd

Data source: Immodulon Therapeutics Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• London, United Kingdom